MDR Article 61 · Annex XIV · Class I
Class I does not mean clinical evidence is optional
The evidence package may be proportionate. The reasoning still has to be rigorous.
A simple device can have a concise clinical evaluation, but not an empty one. The manufacturer must connect the intended purpose, clinical claims, risks, available data and post-market plan into a defensible clinical story.
Start with the device route ↓The rule in one sentence
Risk class changes the depth of the evaluation, not the obligation to perform it
01The manufacturer must specify and justify the clinical evidence level appropriate to the device and its intended purpose.
02The evaluation must be planned, methodologically sound, documented in a CER and updated throughout the device lifecycle.
First question
Which Class I route actually applies?
All four routes require technical documentation and clinical evaluation. What changes is whether a notified body has a limited role in the conformity assessment.
Manufacturer self-declaration
Technical documentation comes before the declaration
The manufacturer draws up the Annex II and III technical documentation, completes the clinical evaluation and issues the EU declaration of conformity. Self-declaration is not evidence exemption.
- No notified body for the ordinary Class I route
- Clinical Evaluation Plan and Clinical Evaluation Report required
- Class I PMS report under MDR Article 85
Limited notified-body involvement
The notified-body scope is focused on sterility
The notified body is involved in the aspects relating to establishing, securing and maintaining sterile conditions. The manufacturer remains responsible for the complete clinical evaluation and technical documentation.
- Sterilisation and sterile-barrier validation remain critical
- Clinical claims still require appropriate support
- PMS must monitor device and sterility-related signals
Limited notified-body involvement
The notified-body scope is focused on metrology
The notified body addresses conformity with the metrological requirements. Accuracy, precision, calibration and clinically meaningful performance claims must remain consistent across verification, risk management and the CER.
- Measurement claims define the required evidence
- Bench performance and clinical context must connect
- Drift and use error belong in post-market monitoring
Limited notified-body involvement
The notified-body scope is focused on safe reuse
The notified body addresses cleaning, disinfection, sterilisation, maintenance, functional testing and the related instructions for use. The clinical evaluation must still support the intended clinical function and safety.
- Reusable scalpel handles normally belong here
- Reprocessing validation is part of the evidence system
- Lifetime and degradation claims require verification
The evidence workflow
Build the CER from claims outward
Starting with a literature search is tempting. Starting with the intended purpose and the claims prevents a beautifully documented search from answering the wrong questions.
Lock the intended purpose
Define users, patient population, indications, contraindications, anatomical site, duration, operating principle and product variants.
Translate claims into outcomes
State what the device is expected to achieve clinically and identify the safety, performance and benefit-risk questions to be answered.
Justify the evidence depth
Consider novelty, contact with the body, clinical claims, known risks, state of the art, product history and uncertainty.
Identify and appraise evidence
Search systematically, include favourable and unfavourable data, assess relevance and quality, and expose the gaps.
Generate what is missing
Use the right method for each gap. That may be bench testing, preclinical work, usability data, PMCF or a clinical investigation.
Conclude, monitor and update
Align the CER with risk management, GSPR evidence, labelling, PMS and PMCF, then define when new information triggers review.
Proportionate does not mean superficial
A Class I evidence package is usually mixed
Clinical evidence rarely comes from one perfect source. The CER should explain what each source contributes and where it cannot carry the argument.
Bench, biocompatibility and usability testing are not automatically clinical data. They can still be essential non-clinical evidence supporting safety, performance and the justification of the clinical evidence level.
Direct device data
Clinical investigations, published experience, complaints, vigilance, PMCF and real-world use relating to the evaluated device.
Equivalent-device data
Clinical data may support conformity only when technical, biological and clinical equivalence is demonstrated and data access is sufficient.
Similar devices and state of the art
Useful for clinical background, benchmark outcomes, known risks and alternative options, but not automatically proof for the subject device.
Non-clinical verification
Performance, biological safety, usability, packaging, sterilisation, reprocessing and shelf-life data close specific technical questions.
Post-market evidence
Sales exposure, complaints, trend data, literature, user feedback, incidents and PMCF test whether the pre-market conclusions remain true.
The equivalence trap
“Similar” is a search term. “Equivalent” is a conclusion.
Decades of use by comparable products can be valuable. It does not remove the need to show why their data apply to your device.
Does the device work in materially the same way?
Compare design, specifications, physicochemical properties, conditions of use, deployment, operating principle and critical performance.
Does the body encounter the same materials?
Compare materials and substances, contact tissues and fluids, contact type and duration, and release characteristics including degradation products and leachables.
Is the clinical context genuinely comparable?
Compare purpose, condition, severity, body site, population, intended user, critical performance and the expected clinical effect.
Do you need a clinical investigation?
Class I is not the answer. Evidence sufficiency is.
MDR does not automatically require a pre-market clinical investigation for every Class I device. Annex XIV does require new clinical data when the available evidence leaves relevant questions unresolved.
Are the intended purpose and claims conventional?
Novel claims can raise the evidence requirement even when the hardware appears simple.
Is the available evidence directly relevant?
General literature about a product category may not support a specific performance or benefit claim.
Can every material gap be closed without human data?
Article 61(10) requires a device-specific justification when non-clinical methods alone are considered adequate.
What uncertainty remains after risk controls?
If a clinically important question remains open, a focused investigation or PMCF activity may be the shortest defensible route.
Document why the combined clinical and non-clinical evidence supports each claim and relevant GSPR. Define proportionate post-market confirmation.
Generate targeted data. Do not disguise an unresolved clinical question as a generic “low-risk device” justification.
Two worked scenarios
The intended purpose changes the evidence story
Product names do not determine classification. The claims, contact, mode of action and conditions of use do.
Non-sterile adhesive dressing for a superficial injury
Assume the intended purpose is limited to acting as a mechanical barrier and absorbing exudate from a minor superficial injury.
MDR Rule 4 places wound-contact devices in Class I when they are intended as a mechanical barrier, for compression or for absorption of exudates.
State-of-the-art literature, material and biocompatibility data, adhesive and absorption performance, skin-reaction risks, usability, comparable market experience and PMS.
A dressing intended to manage the wound micro-environment is generally Class IIa. A product principally intended for certain deeper wounds healing by secondary intent can be Class IIb.
Reusable scalpel handle without an active-device connection
Assume the instrument is intended for surgical cutting, is reused after validated reprocessing and meets the MDR definition of a reusable surgical instrument.
Rule 6 places reusable surgical instruments in Class I, while Article 52(7) requires limited notified-body involvement for the reuse-related aspects.
Clinical and state-of-the-art literature, functional and material evidence, usability and handling, validated cleaning and sterilisation, reuse-cycle testing, degradation limits, risk management and PMS.
Reprocessing validation does not replace clinical evaluation. It answers an essential reuse question within the wider safety and performance case.
After CE marking
The CER becomes a loop, not an archive
Article 61 requires the clinical evaluation and its documentation to be updated throughout the device lifecycle using PMCF and PMS information.
Manufacturers prepare a PMS report under Article 85 rather than the PSUR required for Classes IIa, IIb and III. The report is updated when necessary.
evaluationCurrent conclusion
What weak Class I CERs get wrong
Seven shortcuts that create longer reviews later
The recurring problem is not a short report. It is a report whose conclusions cannot be traced back to the device, the claims and the data.
- 01
Using “Class I” as the justification for a low evidence level instead of analysing device characteristics, intended purpose, claims and risks.
- 02
Calling competitor products equivalent without a technical, biological and clinical comparison or sufficient access to the underlying data.
- 03
Presenting bench or biocompatibility testing as clinical data instead of explaining its proper role in the overall evidence package.
- 04
Searching only for favourable publications and omitting known adverse effects, recalls, safety notices or alternative treatments.
- 05
Writing a literature summary without defining acceptance criteria, appraising study quality or mapping evidence to claims and GSPRs.
- 06
Waiving PMCF with a generic sentence rather than a device-specific justification supported by the CER, risk management and PMS strategy.
- 07
Allowing the CER, risk file, IFU, marketing claims and post-market plan to describe slightly different products.
Practical questions
Class I clinical evaluation FAQ
The shortest reliable answer is usually conditional. Open each question for the boundary that matters.
Does every Class I medical device need a Clinical Evaluation Report?+
Yes. MDR Article 61 and Annex XIV require the clinical evaluation, its results and the clinical evidence to be documented in a CER that forms part of the technical documentation.
Does every Class I device need a clinical investigation?+
No. The need depends on whether the available clinical and non-clinical evidence is sufficient for the intended purpose, claims, risks and relevant GSPRs. New clinical data are needed when material clinical gaps remain.
Can literature about competitor devices support the CER?+
Yes, but its role must be clear. Similar-device literature can establish the state of the art and known risks. Reliance on another device's clinical data as evidence for conformity requires a defensible equivalence demonstration.
Can PMCF be considered not applicable for a simple Class I device?+
Potentially, but the technical documentation must contain a device-specific justification. The manufacturer must still maintain PMS, review new clinical information and update the clinical evaluation throughout the lifecycle.
Does a notified body approve the full CER for Class Is, Im or Ir?+
Article 52(7) limits the notified body's mandated involvement to sterility, metrological or reuse-related aspects, as applicable. The manufacturer remains responsible for the complete clinical evaluation and technical documentation.
Primary regulatory sources
Go back to the rule when the answer feels too easy
MDCG documents are guidance and do not replace the Regulation. They help translate the legal requirements into a reviewable evidence process.
From “low risk” to defensible evidence
Need a Class I clinical evaluation that is proportionate without being fragile?
MDRC can review the classification, define the clinical evidence strategy, identify avoidable gaps and prepare or update the CEP and CER.
